Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 21, Issue 12, Pages 1630-1642
Publisher
Elsevier BV
Online
2020-10-31
DOI
10.1016/s1470-2045(20)30525-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The multiple myelomas — current concepts in cytogenetic classification and therapy
- (2018) Shaji K. Kumar et al. Nature Reviews Clinical Oncology
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- Patient subgroup identification for clinical drug development
- (2017) Xin Huang et al. STATISTICS IN MEDICINE
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
- (2015) S M Matulis et al. LEUKEMIA
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
- (2015) Charlotte Kervoëlen et al. Oncotarget
- The Tao of myeloma
- (2014) L. H. Boise et al. BLOOD
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- ABT-737 is highly effective against molecular subgroups of multiple myeloma
- (2011) L. Bodet et al. BLOOD
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now